Zhao Jane, Bader Andreas G
Mirna Therapeutics, Inc., 2150 Woodward Street, Suite 100, Austin, TX, 78744, USA.
Methods Mol Biol. 2017;1517:115-126. doi: 10.1007/978-1-4939-6563-2_8.
Tumor suppressor miRNAs such as miR-34a inhibit tumor growth by simultaneously regulating the expression of multiple important oncogenes across multiple oncogenic pathways and, therefore, provide a strong rationale for developing therapeutic miRNA mimics in combination with other therapeutic cancer agents to augment drug sensitivity. Here, we describe the experimental approach for evaluating miRNA and drug combinations using the "fixed ratio" method in cultured non-small cell lung cancer cells.
肿瘤抑制性微小RNA（如miR-34a）通过同时调节多个致癌途径中多个重要癌基因的表达来抑制肿瘤生长，因此，为开发治疗性微小RNA模拟物与其他癌症治疗药物联合使用以增强药物敏感性提供了有力的理论依据。在此，我们描述了在培养的非小细胞肺癌细胞中使用“固定比例”方法评估微小RNA与药物组合的实验方法。
Zotero 插件